Segment Information (Tables)

3 Months Ended

Mar. 31, 2013



	Three Months Ended
	March 31,
	2013			2012
Segment revenue — to unaffiliated customers:
Human pharmaceutical products:
Neuroscience	$	1,848.8		$	1,903.7
Endocrinology	1,724.9			1,690.9
Oncology	764.2			803.9
Cardiovascular	693.9			638.4
Other pharmaceuticals	71.1			74.4
Total human pharmaceutical products	5,102.9			5,111.3
Animal health	499.1			490.7
Total segment revenue	$	5,602.0		$	5,602.0
Segment profits:
Human pharmaceutical products	$	1,348.2		$	1,231.7
Animal health	129.2			127.4
Total segment profits	$	1,477.4		$	1,359.1
Reconciliation of total segment profits to consolidated income before taxes:
Segment profits	$	1,477.4		$	1,359.1
Other profits (losses):
Income related to transfer of exenatide commercial rights (Note 4)	495.4			—
Asset impairments, restructuring, and other special charges (Note 5)	(21.7		)	(23.8		)
Total consolidated income before taxes	$	1,951.1		$	1,335.3

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details